• Mechanism

  • Disease areas


Medivir’s Metallo Beta Lactamase (MBLI) program aimed at addressing the threat of resistant bacteria was out-licensed in 2017 to the AMR Centre (today INFEX Therapeutics) in England.

In 2022, INFEX presented additional preclinical data, received patent approval for the substance in the United States, and communicated its intention to initiate a phase I program in 2023 for MET-X. In January, MET-X received QIDP-designation from the FDA. Medivir is entitled to a share of potential future revenue.